
mAbxience will develop and manufacture the antibody for ONC001, a CD64-targeting ADC aimed at monocytic AML and chronic myelomonocytic leukemia.
Representatives of contract service organizations discuss technology trends with BioPharm International.
from BioPharm International’s 2014 Outsourcing Strategies eBook.
View other articles in the
.
about 12 years ago
Biopharma Contract Manufacturing Prices Go Up—and Downabout 12 years ago
Ensuring Sound Bioanalytical Methods Transferabout 12 years ago
Weighing Clinical Trial Outsourcing Optionsover 12 years ago
Outsourcing Trends in Biopharmaceutical Manufacturing




